B.Riley raises Axsome Therapeutics price target on sales guidance By Investing.com

Axsome Therapeutics reported Q1 2026 revenue of $191 million, up 57% year over year and above the $188 million consensus, while Auvelity net sales reached $153.2 million versus $148.2 million expected. The company raised Auvelity peak sales guidance to about $8 billion from a previous midpoint of $4 billion, and multiple firms lifted price targets, including B.Riley to $300 and RBC to $302. Management also flagged a June 2026 full commercial launch for dementia-related agitation and said it expects to break even on cash flow in 2026.

Analysis

The cleaner read-through is that Apple/TSMC diversification chatter is less about near-term wafer displacement and more about bargaining power and supply-chain optionality. If Apple meaningfully dual-sources even a modest share, the second-order effect is margin pressure on the foundry ecosystem: TSMC’s pricing leverage weakens at the high end, while Intel becomes a strategic hedge asset rather than a pure earnings story. The market is likely pricing the symbol, not the timeline; any real revenue inflection for Intel would be measured in years, not quarters, because qualifying advanced nodes and packaging across Apple’s product cycle is a slow-motion process.

For Axsome, the key is not the raised guidance itself but the implied duration of operating leverage. A stock at this setup typically trades less on current quarter revenue and more on whether the street is forced to re-rate the peak-sales base upward in successive steps; that can keep the multiple expanding even before the new indication fully ramps. The risk is execution latency: if the launch curve for the new use case is back-end loaded, investors may be over-assigning 2026/2027 cash generation and underestimating the working-capital and commercial spend needed to support the larger sales force.

Consensus appears to be treating the move as a clean bullish de-risking, but that may be too linear. The more interesting contrarian angle is that the biggest upside may come from portfolio rotation, not absolute upside: long the under-owned, cash-generative growth compounder and fade the foundry headline beta if there is no follow-through from Apple. In other words, the article is bullish on both, but the risk/reward is asymmetric in timing — Axsome can compound on visible catalysts over the next 6-12 months, while Intel’s story remains a call option on a partnership process that can easily disappoint before it monetizes.

Key Decisions for Investors

• Long AXSM on pullbacks over the next 1-2 weeks; target a 3-6 month horizon into launch and Phase 3 catalysts. Favor equity over options because the setup is driven by repeated guidance revisions and de-risking, not a single binary event.
• Buy AXSM call spreads expiring after the key 2H26 readouts; structure for upside into the next catalyst window while capping premium bleed if launch adoption is slower than expected.
• Relative-value: long AXSM / short a basket of large-cap pharma with slower growth and lower catalyst density over the next 3-6 months. The trade monetizes rerating dispersion as investors pay up for visible pipeline-to-sales conversion.
• Avoid chasing INTC on the Apple headline; if trading it, use a short-dated call spread only after confirmation of a concrete supplier qualification milestone. The risk/reward is poor until there is evidence of actual volume allocation.
• If you want to express the Apple diversification theme, prefer a cautious TSM hedge via a small short or put spread versus any long INTC exposure. That captures potential incremental pricing pressure at TSM while limiting reliance on a very long-dated Intel execution story.